NGC Update Service: July 15, 2013

July 15, 2013 New This Week Guideline Summaries British Committee for Standards in Haematology Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients. Bureau of Health Promotion, Department of Health, Taiwan Taiwan osteoporosis practice guidelines. Canadian Cardiovascular Society New Developer Management of patients with refractory angina: Canadian Cardiovascular Society/Canadian Pain Society joint guidelines. European Association of Urology Nurses Catheterisation. Urethral intermittent in adults: dilatation, urethral intermittent in adults. Institute for Clinical Systems Improvement Antithrombotic therapy supplement. This updates a previously published guideline summary. Venous thromboembolism diagnosis and treatment. This updates a previously published guideline summary. National Institute for Health and Care Excellence (NICE) Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation. Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy. Ranibizumab for treating diabetic macular oedema (rapid review of technology appraisal guidance 237). Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract. National Society of Genetic Counselors NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. This updates a previously published guideline summary. Announcements Revised Inclusion Criteria NGC has revised its Inclusion Criteria! Visit our updated Inclusion Criteria page to see the new criteria and send us your comments. Conference News The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site. U.S. Food and Drug Administration (FDA) Advisory July 3, 2013: Olmesartan Medoxomil: FDA is warning that the blood pressure drug Olmesartan Medoxomil (marketed as Benicar, Benicar HCT, Azor, Tribenzor, and generics) can cause intestinal problems known as sprue-like enteropathy. Symptoms of sprue-like enteropathy include severe, chronic diarrhea with substantial weight loss. FDA has approved changes to the labels of these drugs to include this concern. FDA will continue to evaluate the safety of olmesartan-containing products and will communicate again if additional information becomes available. NGC's Sister Resources Find Innovations and QualityTools classified by disease or clinical category, patient population, setting of care, stage of care, and more in AHRQ's Health Care Innovations Exchange Web site. Look for Quality Measures in AHRQ's National Quality Measures Clearinghouse (NQMC).    How satisfied are you with this e-mail bulletin? Give Us Your Feedback Subscriber Services: Change Your Profile | Unsubscribe | Help Stay Connected: Contact Us | Social Media This email was sent to buzzhairs.health@blogger.com using GovDelivery, on behalf of: Agency for Healthcare Research and Quality (AHRQ) · 540 Gaither Road · Rockville, MD 20850 · 301-427-1364